Leukemia Research and Treatment

Clinical Study

Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy

Table 1

Clinicobiological characteristics of the patients.
 Patients No. (%)
Age 
 >707 (50)
 <707 (50)
Sex 
 Male10 (71)
 Female 4 (29)
FAB 
 M48 (57)
 M54 (29)
 M62 (14)
Disease status 
 De novo3 (21)*
 Secondary2 (14)**
 Refractory4 (29)
 Relapsed5 (36)
Previous lines of CHT
 
 14
 21
 >24
Peripheral blood blast count
 
 <5 × 109/L9 (64)
 >5 × 109/L5 (36)
Karyotype 
 Intermediate10 (83)
 Unfavorable2 (17)
 Failure2
 *Frails due to age higher than 75 years, one refused conventional chemotherapy.
**Secondary leukemia following myelodysplasia and not eligible for the available conventional protocols.